Literature DB >> 15939720

Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan.

S-Y Huang1, M Yao, J-L Tang, W Tsay, F-Y Lee, M-C Liu, C-H Wang, Y-C Chen, M-C Shen, H-F Tien.   

Abstract

BACKGROUND: The incidence of multiple myeloma (MM) is lower in Asia than in Western countries. However, it is not known whether cytogenetic abnormalities (CA) characteristic of MM in Asia differ from those documented in the West. PATIENTS AND METHODS: We analyzed CA by conventional cytogenetics (CG) and/or fluorescence in situ hybridization (FISH), assessed their clinical significance in 150 Chinese MM patients and compared our data with that derived from Western countries.
RESULTS: CA were detected by CG (CG_CA) in 44 (29.3%) of the 150 patients and by FISH (FISH_CA) in 59 (67%) of the 88 patients studied. Presence of either CG_CA or FISH_CA was associated with a poor prognosis. Patients with CG_CA and hyperdiploid chromosomes, always associated with several trisomies, had a longer survival (median 25 months versus 12 months; P=0.025) in comparison with those with non-hyperdiploid chromosomes, usually associated with a monosomy 13/partial deletion of 13q (Delta13) and a rearrangement of 14q32. A novel recurrent CG_CA, add(19)(p13), was found in four patients: all males with immunoglobulin G/lambda isotypes, extramedullary myeloma at diagnosis and a poor prognosis. Three groups of patients with significantly different survival, CG_Delta13, FISH_Delta13 but without CG_Delta13, and neither CG_Delta13 nor FISH_Delta13 (median 9 versus 15 versus 32 months; P=0.013) were identified.
CONCLUSIONS: We conclude that MM CA in our patients are similar to those noted in Western countries, and that combined CG and FISH analysis can predict prognosis. The clinical significance of add(19)(p13) needs to be further investigated.

Entities:  

Mesh:

Year:  2005        PMID: 15939720     DOI: 10.1093/annonc/mdi273

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  11 in total

1.  Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

Authors:  Cigdem Aydin; Turgay Ulas; Ceren Hangul; Orhan Kemal Yucel; Utku Iltar; Ozan Salim; Deniz Ekinci; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-25       Impact factor: 0.900

2.  Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.

Authors:  E Muchtar; A Dispenzieri; S K Kumar; R P Ketterling; D Dingli; M Q Lacy; F K Buadi; S R Hayman; P Kapoor; N Leung; R Chakraborty; W Gonsalves; R Warsame; T V Kourelis; S Russell; J A Lust; Y Lin; R S Go; S Zeldenrust; R A Kyle; S V Rajkumar; M A Gertz
Journal:  Leukemia       Date:  2016-12-01       Impact factor: 11.528

3.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

4.  Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma.

Authors:  Vincenzo Pitini; Carmela Arrigo; Concetta Alafaci; Giuseppe Altavilla
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

5.  Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.

Authors:  Shang-Yi Huang; Hsiu-Hsia Lin; Ming Yao; Jih-Luh Tang; Shang-Ju Wu; Hsin-An Hou; Wen-Chien Chou; Sheng-Chieh Chou; Szu-Chun Hsu; Bor-Sheng Ko; Hsiao-Yun Lu; Woei Tsay; Hwei-Fang Tien
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

6.  Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Chung-Wu Lin; Hsiu-Hsia Lin; Ming Yao; Jih-Luh Tang; Shang-Ju Wu; Yao-Chang Chen; Hsiao-Yun Lu; Hsin-An Hou; Chien-Yuan Chen; Wen-Chien Chou; Woei Tsay; Sheng-Je Chou; Hwei-Fang Tien
Journal:  Ann Hematol       Date:  2014-04-01       Impact factor: 3.673

7.  Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.

Authors:  Shang-Ju Wu; Chien-Ting Lin; Andreas Agathangelidis; Liang-In Lin; Yuan-Yeh Kuo; Hwei-Fang Tien; Paolo Ghia
Journal:  Haematologica       Date:  2017-03-02       Impact factor: 9.941

8.  Evaluation of chromosomal abnormalities by cIg-FISH and association with proliferative and apoptotic indexes in multiple myeloma.

Authors:  C C G Linardi; G Martinez; E D R P Velloso; A M Leal; C A Kumeda; V Buccheri; R S Azevedo; L M Peliçario; P Dorlhiac-Llacer
Journal:  Braz J Med Biol Res       Date:  2012-08-23       Impact factor: 2.590

Review 9.  Sellar solitary plasmacytoma progressing to multiple myeloma: a case report and literature review.

Authors:  Chang-Zhen Jiang; Qing-Song Lin; Xi-Yue Wu; Chen-Yang Wang; De-Zhi Kang
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

10.  Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Hsiu-Hsia Lin; Chung-Wu Lin; Chi-Cheng Li; Ming Yao; Jih-Luh Tang; Hsin-An Hou; Woei Tsay; Sheng-Je Chou; Chieh-Lung Cheng; Hwei-Fang Tien
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.